[5].Watanabe, N., et al., Long-Term Outcomes of 107 Cases of Primary Thyroid Mucosa-Associated Lymphoid Tissue Lymphoma at a Single Medical Institution in Japan. J Clin Endocrinol Metab, 2018. 103(2): p. 732-739.
At the interim analysis, 30 response-evaluable patients treated with 20 mg lenalidomide were enrolled, and 18 responders (60%) were observed. The results were reviewed by a review committee comprising the Sponsor (the ...
ObjectiveTo evaluate the treatment outcome, prognostic factors, radiation dose, and toxicities in patients with early-stage primary diffuse large B-cell lymphoma of Waldeyer’s ring (WR-DLBCL) treated with intensity-modulated radiotherapy (IMRT). MethodsThis study included 80 patients with a confirmed...
Learn how ADC Therapeutics is confronting an unmet medical need in patients with DLBCL by developing the next generation of antibody drug conjugates (ADCs).
DLBCL.Borchmann: JULIET is a very important trial in patients with relapsed/refractory DLBCL failing at least 2 prior lines of systemic therapies. In this patient population, we have a very high unmet medical need. The OS in this patient cohort is short, with a median OS of approximately 4...
2. Duell J, Maddocks KJ, González-Barca E, et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.Haematologica. 2021;106(9):2417-2426. Published 2021 Sep 1. d...
The use of tafasitamab-cxix (Monjuvi), lenalidomide (Revlimid), rituximab (Rituxan), and acalabrutinib (Calquence; LTRA) in the first-line setting induced high responses in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), with responders deriving benefit from subsequent treat...
(Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) shows promising efficacy in non-germinal center B cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) with extranodal disease, according to results presented at the 2022 European Society for Medical Oncology Cong...
Diffuse large B-cell lymphoma (DLBCL) represents a prevalent malignant tumor, with approximately 40% of patients encountering treatment challenges or relapse attributed to rituximab resistance, primarily due to diminished or absent CD20 expression. Our p
DLBCL patients, especially those with a history of ineffective treatments, including salvage chemotherapy and autologous stem cell transplantation, often face bleak prognoses. CAR-T cell therapy, although effective for some, only offers long-term remission in about 40 percent of cases. In this context...